Citations

Clear

2960 citation(s) found for "Kim, In-Ho".

Common Kibra Alleles Are Associated with Human Memory Performance
Papassotiropoulos, Andreas , Stephan, Dietrich , Huentelman, Matthew J. , Craig, David W. , Pearson, John V. , Huynh, Kim-Dung, Brunner, Fabienne, Corneveaux, Jason J., Osborne, David, Wollmer, M. Axel, Aerni, Amanda , Coluccia, Daniel , Hänggi, Jürgen , Mondadori, Christian R.A., Buchmann, Andreas , Reiman, Eric M. , Caselli, Richard J. , Quervain, Dominique J.‐F. de , Hoerndli, Frédéric J. , Henke, Katharina

Mayo Clinic

Science | October 19, 2006 | Volume: 314 | Issue: 5798 | Pages: 475-478

10.1126/science.1129837 | PMID 17053149 Get It

Human memory is a polygenic trait. We performed a genome-wide screen to identify memory-related gene variants. A genomic locus encoding the brain protein KIBRA was significantly associated with memory performance in three independent, cognitively normal cohorts from Switzerland and the United States. Gene expression studies showed that KIBRA was expressed in memory-related brain structures. Functional magnetic resonance imaging detected KIBRA allele–dependent differences in hippocampal activations during memory retrieval. Evidence from these experiments suggests a role for KIBRA in human memory.
P1–005: RAAV vectors to rapidly modify and model AD pathology in mice, rats, and guinea pigs
Golde, Todd E. , Jansen, Karen, Nyborg, Andrew C., Das, Pritam , Chakrabarty, Paramita , Smithson, Lisa, Kim, Jungsu , Levties, Yona, Kim, Jungsu

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_4 | Pages: No page available

10.1016/j.jalz.2006.05.380 Get It

O4–05–05: Dissociation between amyloid pathology and memory impairment
Janus, Christopher , Kim, Jungsu , Hanna, Amanda, Wilson, Judith, Price, Robert, Golde, Todd E. , Dickson, Dennis W. , McGowan, Eileen , Kim, Jungsu

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_3 | Pages: No page available

10.1016/j.jalz.2006.05.331 Get It

P4–196: The capacity of persons with very mild to moderate AD to provide informed consent to enroll in a clinical trial
Karlawish, Jason , vanDyck, Christopher, Marson, Daniel , Kim, Scott Y. H. , Knopman, David S. , James, Bryan D.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_19 | Pages: No page available

10.1016/j.jalz.2006.05.1935 Get It

Individual Measurement and Significance of Carotid Intima, Media, and Intima–Media Thickness by B-Mode Ultrasonographic Image Processing
Bae, Jang‐Ho , Kim, Wuon‐Shik , Rihal, Charanjit S. , Rihal, Charanjit S. , Lerman, Amir

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | August 11, 2006 | Volume: 26 | Issue: 10 | Pages: 2380-2385

10.1161/01.atv.0000240420.36229.f9 | PMID 16902160 Get It

Objective— We assessed the clinical significance of intima (IT), media (MT), and intima–media (IMT) thickness of the common carotid artery using B-mode ultrasonographic image processing. Methods and Results— One hundred seventy consecutive patients underwent common carotid artery scanning using high-resolution ultrasonography. A total of 150 patients could be analyzed off-line using ultrasonographic image processing, devised for individual measurement of IT, MT, and IMT. By univariate analysis, IT (range, 0.27 to 0.41 mm) was associated with age, whereas MT (range, 0.27 to 0.74 mm) and IMT (range, 0.49 to 1.12 mm) were associated with age, fibrinogen, and creatinine. Among atherosclerosis risk factors, hypertension was associated with thickness of all 3 layers, whereas smoking was associated with IT only. By multivariate analysis, IT was associated with age, hypertension, and smoking, whereas MT and IMT were associated with age, hypertension, and blood urea nitrogen level. Conclusions— Carotid IT is associated with smoking, whereas age and hypertension are associated with thickness of all 3 arterial layers. Our results suggest a differential response of the vasculature to systemic risk factors.
Role and Results of Surgery in Acute Type B Aortic Dissection
Trimarchi, Santi , Rampoldi, Vincenzo, Myrmel, Truls , Bossone, Eduardo , Tolva, Valerio , Deeb, Michael G., Cooper, Jeanna V., Fang, Jianming, Sundt, Thoralf M. , Nienaber, Christoph , Suzuki, Toru , Upchurch, Gilbert R. , Isselbacher, Eric M. , Eagle, Kim A. , Bossone, Eduardo

Mayo Clinic

Circulation | July 7, 2006 | Volume: 114 | Issue: 1_supplement | Pages: No page available

10.1161/circulationaha.105.000620 | PMID 16820600 Get It

Background— The clinical profiles and outcomes of patients treated surgically for acute type B aortic dissection (ABAD) are often reported for those in small series or for those cared for at a single institution over a long time period, during which a continuous evolution in techniques has occurred. Accordingly, we sought to evaluate the clinical features and surgical results of patients enrolled in the International Registry of Acute Aortic Dissection by identifying primary factors that influenced surgical outcome and estimating average surgical mortality for ABAD in the current era. Methods and Results— A comprehensive analysis of 290 clinical variables and their relation to surgical outcomes for 82 patients who required surgery for ABAD (from a population of 1256 patients; mean±SD age, 60.6±15.0 years; 82.9% male) and who were enrolled in the International Registry of Acute Aortic Dissection was performed. The overall in-hospital mortality was 29.3%. Factors associated with increased surgical mortality based on univariate analysis were preoperative coma or altered consciousness, partial thrombosis of the false lumen, evidence of periaortic hematoma on diagnostic imaging, descending aortic diameter >6 cm, right ventricle dysfunction at surgery, and shorter time from the onset of symptoms to surgery. Factors associated with favorable outcomes included radiating pain, normotension at surgery (systolic blood pressure 100 to 149 mm Hg), and reduced hypothermic circulatory arrest time. The 2 independent predictors of surgical mortality were age >70 years (odds ratio, 4.32; 95% confidence interval, 1.30 to 14.34) and preoperative shock/hypotension (odds ratio, 6.05; 95% confidence interval, 1.12 to 32.49). Conclusions— The present study provides insights into current-day clinical profiles and surgical outcomes of ABAD. Knowledge about different preoperative clinical conditions may help surgeons in making treatment decisions among these high-risk patients.
Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer
Mahoney, Michelle R., Allmer, Cristine, Pitot, Henry C., Kim, George , Donehower, Ross C. , Fitch, Tom R., Erlichman, Charles , Philip, Philip A. , Thomas, James P. , Picus, Joel

Mayo Clinic

Journal of Clinical Oncology | June 30, 2006 | Volume: 24 | Issue: 19 | Pages: 3069-3074

10.1200/jco.2005.05.3579 | PMID 16809731 Get It

Purpose Epidermal growth factor receptor/human epidermal growth factor receptor 1 and ligand expression is common in biliary cancers (BILI) and may be associated with worse outcome. The primary objective of this study was to determine the proportion of patients with advanced BILI who were progression-free at 6 months. Methods Patients with either unresectable or metastatic disease were studied. Only one prior systemic or locoregional therapy was allowed. Erlotinib was administered continuously at a dose of 150 mg per day orally. Results Forty-two patients with BILI were enrolled. The median age was 67 years (range, 33 to 82 years). Fifty-two percent of patients had Eastern Cooperative Oncology Group performance status of 1. Fifty-seven percent of patients had received prior chemotherapy for advanced BILI. HER1/EGFR expression by immunohistochemistry in tumor cells was detected in 29 (81%) of the 36 assessable patients. Seven of the patients (17%; 95% CI, 7% to 31%) were progression free at 6 months. Three patients had partial response by Response Evaluation Criteria in Solid Tumors Group classification of duration 4, 4, and 14 months, respectively. All responding patients had mild (grade 1/2) skin rash and two patients had positive tumoral HER1/EGFR expression. Three patients (7%) had toxicity-related dose reductions of erlotinib due to grade 2/3 skin rash. Conclusion Results suggest a therapeutic benefit for EGFR blockade with erlotinib in patients with biliary cancer. Additional studies with erlotinib as a single agent and in combination with other targeted agents are warranted in this disease.
Secondary Structure and Interfacial Aggregation of Amyloid-β(1−40) on Sodium Dodecyl Sulfate Micelles
Rangachari, Vijayaraghavan , Reed, Dana Kim , Moore, Brenda D. , Rosenberry, Terrone L.

Mayo Clinic

Biochemistry | June 22, 2006 | Volume: 45 | Issue: 28 | Pages: 8639-8648

10.1021/bi060323t | PMID 16834338 Get It

Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward
Kelloff, Gary J. , Lippman, Scott M. , Dannenberg, Andrew J. , Sigman, Caroline C. , Pearce, Homer L., Reid, Brian J. , Szabó, Éva , Jordan, V. Craig , Spitz, Margaret R., Papadimitrakopoulou, Vali A., Lotan, Reuben, Aggarwal, Bharat B. , Bresalier, Robert S. , Kim, Jeri , Lu, Karen H. , Thomas, Melanie E., Rhodes, Helen, Brewer, Molly, Follen, Michele , Shin, Dong M. , Parnes, Howard L. , Siegfried, Jill M. , Evans, Alison A., Blot, William J. , Chow, Wong‐Ho , Blount, Patricia L., Wang, Kenneth K. , Lam, Stephen , Lee, J. Jack, Dubinett, Steven M., Engstrom, Paul F., Meyskens, Frank L. , O’Shaughnessy, Joyce , Hawk, Ernest T. , Levin, Bernard, Nelson, William G. , Hong, Waun Ki , Prevention, for the AACR Task Force on Cancer, Lee, J. Jack , Mills, Gordon B. , Arun, Banu , Maley, Carlo C. , Lee, J. Jack, Prevention, for the AACR Task Force on Cancer, Szabo, Eva , Lee, J Jack

Mayo Clinic

Clinical Cancer Research | June 8, 2006 | Volume: 12 | Issue: 12 | Pages: 3661-3697

10.1158/1078-0432.ccr-06-1104 | PMID 16778094 Get It

AbstractThis article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point selection for clinical trials. We outline the concept of augmenting the risk, mechanistic, and disease data from histopathologic intraepithelial neoplasia assessments with molecular biomarker data. Updates of work in 10 clinical target organ sites include new data on molecular progression, significant completed trials, new agents of interest, and promising directions for future clinical studies. This overview concludes with strategies for accelerating chemopreventive drug development, such as integrating the best science into chemopreventive strategies and regulatory policy, providing incentives for industry to accelerate preventive drugs, fostering multisector cooperation in sharing clinical samples and data, and creating public-private partnerships to foster new regulatory policies and public education.
Further characterization of the receptor-binding region of the thyroid-stimulating hormone alpha subunit: a comprehensive synthetic peptide study of the alpha-subunit 26-46 sequence.
Leinung, Matthew C., Reed, Dana Kim , McCormick, Daniel , Ryan, Robert J. , Morris, James C.

Mayo Clinic

Proceedings of the National Academy of Sciences | May 31, 2006 | Volume: 88 | Issue: 21 | Pages: 9707-9711

10.1073/pnas.88.21.9707 | PMID 1946392 Get It

Previously, using a synthetic peptide strategy, we determined that the region of the common glycoprotein hormone alpha subunit between residues 26 and 46 is a site of interaction of the hormone with the thyroid membrane-bound receptor for thyroid-stimulating hormone (TSH). We have undertaken to identify further the specific residues within this 21-amino acid span that are critical in hormone receptor binding. We synthesized three nested sets of peptide, two in which we systematically truncated the amino-terminal region of the sequence and another in which we truncated the carboxyl-terminal region, and we synthesized a fourth nested set in which we systematically substituted alanine for the native residues from the region of highest activity. Each peptide was tested in a TSH radioreceptor assay for its ability to inhibit binding of 125I-labeled bovine TSH to porcine thyroid membranes. Removal either by truncation or alanine substitution, of several specific residues resulted in a significant reduction in the ability of the sequence to interact with receptor; these residues included Cys31, Cys32, Phe33, Arg35, Arg42, Lys44, and Lys45, suggesting that they are crucial for binding activity. Loss of activity also occurred with substitution for Gly30 and Ser34, but the reduction was less pronounced. Amino-terminal truncation of the sequence through Arg35 (leaving the alpha-subunit peptide 36-46) resulted in greater than 98% loss of activity of the sequence. We conclude that two distinct receptor binding regions lie within the alpha-subunit 26-46 sequence. The first lies between residues Gly30 and Arg35 and includes Cys31, Cys32, and Phe33 as important constituents, and the second region lies between residues Arg42 and Lys45 and includes Lys44 as an important residue and Ser43 as a less important component.